{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV&page=5", "query": { "intervention": "EBV", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 168, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T08:30:54.993Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06682442", "title": "Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nasopharyngeal Carcinoma", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Nasopharyngeal Cancer", "Nasopharyngeal Cancer Stage" ], "interventions": [ { "name": "Intensity-Modulated Radiation Therapy (IMRT)", "type": "RADIATION" }, { "name": "Radiographic Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2025-03-18", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682442" }, { "nct_id": "NCT02285062", "title": "Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 570, "start_date": "2015-02-17", "completion_date": "2022-07-28", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 22, "location_summary": "Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285062" }, { "nct_id": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma", "EBV-Related Gastric Carcinoma", "EBV-Related Leiomyosarcoma", "EBV Related Carcinoma", "EBV-Related Sarcoma" ], "interventions": [ { "name": "Nanatinostat", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viracta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-10-08", "completion_date": "2025-01-10", "has_results": true, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 3, "location_summary": "Stanford, California • Aurora, Colorado • Houston, Texas", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05166577" }, { "nct_id": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma", "Nasopharyngeal Neoplasms", "Epstein-Barr Virus Infections", "Epstein-Barr Viraemia", "Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)" ], "interventions": [ { "name": "Tabelecleucel", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 12, "start_date": "2019-02-19", "completion_date": "2021-08-19", "has_results": true, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 7, "location_summary": "Duarte, California • Palo Alto, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03769467" }, { "nct_id": "NCT01058239", "title": "Bortezomib Plus Rituximab for EBV+ PTLD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-transplant Lymphoproliferative Disease", "Solid Organ Transplant", "Stem Cell Transplant (Bone Marrow Transplant)", "Epstein Barr Virus Infections" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2011-11", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058239" }, { "nct_id": "NCT07184528", "title": "PATCHVALVE: Endobronchial Valves Plus Blood Patch for Persistent Air Leaks", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Persistent Air Leaks" ], "interventions": [ { "name": "Endobronchial Blood Patch", "type": "DEVICE" }, { "name": "Spiration Valve System (SVS) Placement", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-07-01", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07184528" }, { "nct_id": "NCT05305040", "title": "Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Adenovirus Infection", "BK Virus Infection", "Cytomegalovirus Infections", "Epstein-Barr Virus Infections", "Human Herpes Virus-6 Infection", "JC Virus Infection" ], "interventions": [ { "name": "Posoleucel (ALVR105)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 451, "start_date": "2022-03-24", "completion_date": "2024-01-30", "has_results": true, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05305040" }, { "nct_id": "NCT01945619", "title": "Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "EBV Infection", "CMV Infection", "Adenoviral Infection" ], "interventions": [ { "name": "Trivirus-Specific CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-01-21", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945619" }, { "nct_id": "NCT06256484", "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ATA3219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1, "start_date": "2024-09-06", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 4, "location_summary": "Orlando, Florida • Louisville, Kentucky • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06256484" }, { "nct_id": "NCT06091995", "title": "Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Use of Belatacept in Kidney Transplant Patients" ], "interventions": [ { "name": "impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Methodist Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 67, "start_date": "2022-08-22", "completion_date": "2025-07-07", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-31T08:30:54.993Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06091995" } ] }